Stephen Edward Hiscox

TL;DR: With resources to conduct further high-quality targeted research focusing on the gaps identified, increased knowledge translating into improved clinical care should be achievable within five years.

TL;DR: It is concluded that in breast and prostate cancer cells acquired resistance to gefitinib is associated with increased signalling via the IGF-1R pathway, which also plays a role in the invasive capacity of the gefitsinib-resistant phenotype.

TL;DR: The HGF/SF receptor and intracellular signalling, Ras, rho, raf and rac are involved in c-met cell signalling, and Stimulation of MAP kinase pathways.

TL;DR: Results suggest that homotypic adhesion in tamoxifen‐resistant breast cancer cells is dysfunctional due to EGFR‐driven modulation of the phosphorylation status of β‐catenin and may contribute to an enhanced aggressive phenotype and transition towards a mesenchymal phenotype in vitro.

TL;DR: Observations suggest that Src plays a pivotal role in mediating the motile and invasive phenotype observed in endocrine-resistant breast cancer cells, and the use of Src inhibitors in conjunction with EGFR inhibitors such as gefitinib may provide an effective method with which to prevent cancer progression and metastasis.